Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of "Hold" from Analysts

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) has received a consensus rating of "Hold" from the nineteen ratings firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $37.59.

A number of analysts have weighed in on EXEL shares. Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Exelixis in a research note on Thursday, March 27th. Oppenheimer lowered shares of Exelixis from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $41.00 to $33.00 in a research report on Friday, January 24th. UBS Group reiterated an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Finally, Stephens reiterated an "equal weight" rating and set a $29.00 price target on shares of Exelixis in a research report on Wednesday, February 12th.

Insider Activity

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the transaction, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at $28,174,996.98. This represents a 3.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Dana Aftab sold 1,508 shares of the firm's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the transaction, the executive vice president now directly owns 693,181 shares in the company, valued at approximately $27,034,059. This represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 141,851 shares of company stock valued at $5,236,046 in the last quarter. Company insiders own 2.82% of the company's stock.

Institutional Investors Weigh In On Exelixis

A number of large investors have recently modified their holdings of EXEL. GAMMA Investing LLC grew its stake in shares of Exelixis by 37.2% in the fourth quarter. GAMMA Investing LLC now owns 4,129 shares of the biotechnology company's stock worth $137,000 after purchasing an additional 1,119 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Exelixis by 5.1% during the fourth quarter. Nordea Investment Management AB now owns 233,348 shares of the biotechnology company's stock valued at $7,878,000 after acquiring an additional 11,331 shares during the last quarter. Diversified Trust Co raised its stake in shares of Exelixis by 4.7% during the 4th quarter. Diversified Trust Co now owns 20,136 shares of the biotechnology company's stock worth $671,000 after purchasing an additional 902 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Exelixis by 2.2% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 146,659 shares of the biotechnology company's stock worth $4,884,000 after purchasing an additional 3,112 shares during the period. Finally, Cooper Financial Group lifted its stake in Exelixis by 6.1% in the fourth quarter. Cooper Financial Group now owns 21,377 shares of the biotechnology company's stock valued at $712,000 after purchasing an additional 1,236 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Stock Down 0.1%

Shares of EXEL stock traded down $0.03 during mid-day trading on Friday, reaching $36.95. The company's stock had a trading volume of 3,110,971 shares, compared to its average volume of 2,178,820. The company's 50 day simple moving average is $36.83 and its 200-day simple moving average is $35.49. Exelixis has a 12-month low of $20.14 and a 12-month high of $40.26. The firm has a market capitalization of $10.18 billion, a PE ratio of 20.88, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.12. Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, research analysts anticipate that Exelixis will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.